Allogene raises $120M in convertible notes

Just a few months after raising $300 million in a series A round, cell therapy company Allogene Therapeutics Inc. (South San Francisco, Calif.) raised $120 million through the sale of convertible notes.

Perceptive Advisors led the offering, which included fellow new investors Deerfield Management, Fidelity Management and Research, Franklin Templeton Investments, Jennison Associates, Surveyor Capital, T. Rowe Price Associates, venBio Select Advisor and undisclosed mutual funds. The University of California office of the Chief Investment Officer, an existing investor, also participated...